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Abstract
Hypersensitivity reactions to liposomal drugs, often observed with Doxil and AmBisome, can arise from activation of the complement (C)
system by phospholipid bilayers. To understand the mechanism of this adverse immune reaction called C activation-related pseudoallergy
(CARPA), we analyzed the relationship among liposome features, C activation in human serum in vitro, and liposome-induced
cardiovascular distress in pigs, a model for human CARPA. Among the structural variables (surface charge, presence of saturated,
unsaturated, and PEGylated phospholipids, and cisplatin vs. doxorubicin inside liposomes), high negative surface charge and the presence of
doxorubicin were significant contributors to reactogenicity both in vitro and in vivo. Morphological analysis suggested that the effect of
doxorubicin might be indirect, via distorting the sphericity of liposomes and, if leaked, causing aggregation. The parallelism among C
activation, cardiopulmonary reactions in pigs, and high rate of hypersensitivity reactions to Doxil and AmBisome in humans strengthens the
utility of the applied tests in predicting the risk of CARPA.
© 2011 Elsevier Inc. All rights reserved.
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Over the past two decades numerous liposome formulations
have reached advanced clinical trials or approvals as
medicines.1-5 Among these, liposomal doxorubicin (Doxil,
Caelyx, Ben Venue Laboratories, Inc. Bedford, Ohio, for
Centocor Ortho Biotech Products, LP Raritan, New Jersey)6,7
and liposomal amphotericin B (AmBisome, Gilead, Astellas
Pharma US, Inc. North Deerfield, Illinois)8,9 are the best known,
most widely used products. Besides their therapeutic benefits,
however, these and many other liposomal drugs carry an
increased risk for hypersensitivity reactions (HSRs), also
known as infusion reactions. Depending on premedication and
numerous patient and product-related factors, the frequency of
HSRs is in the 2–30% range, for example ~10% with Doxil10
and ~30%with Ambisome.11 The reactions are mostly minor and
transient; however, life-threatening or even deadly reactions can
happen occasionally in a hypersensitive individual. The latter
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fact lends considerable clinical relevance to the phenomenon,
particularly in patients with a background of atopic constitution
and cardiovascular disease.
Previous studies highlighted the non-IgE-mediated, anaphy-
lactoid (pseudoallergic) nature of liposome reactions, pointing to
activation of the complement (C) system as probably the
underlying cause.12-16 Hence the name, C activation-related
pseudoallergy (CARPA).15,16 It was also established earlier that
multilamellarity, large size, and the presence of very high
amounts (71%) of cholesterol in the bilayer membrane13 are
properties that promote C activation and CARPA. Most recently,
the causal role in C activation of acidic phosphate groups on
polyethylene glycol-conjugated (PEGylated) phosphatidyletha-
nolamine (PE) has been demonstrated.17 Nevertheless, lipo-
somes are defined by a large number of chemical and structural
variables whose impacts on C reactivity and CARPA have not
been explored to date.
The goal of the present study was to analyze the effects of
liposomal surface modifications and internal content on C
reactivity and CARPA, using Doxil and AmBisome as known
reactogenic drug controls. Complement activation was assessed
by measuring the formation of S-protein-bound terminal C
complex (membrane attack complex) (SC5b-9) in human serum,
whereas CARPA was evaluated by measuring liposome-induced
cardiopulmonary distress in pigs. The particular liposome
variables studied are summarized in Table 1.
Methods
Materials
Dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phos-
phatidylglycerol (DMPG), cholesterol (Chol), and egg yolk
phosphatidylcholine (EPC) were purchased from Avanti Polar
Lipids Inc. (Alabaster, Alabama). Fully hydrogenated soy
phosphatidylcholine (HSPC) and soy PG (HSPG) were from
Lipoid Inc. (Ludwigshafen, Germany). All lipids had a purity of
≥97%. Zymosan was from Sigma Chemical Co. (St. Louis,
Missouri). Commercial Doxil (Ben Venue Laboratories, Inc.),
doxorubicin (TEVA Pharmaceuticals, Petach Tikva, Israel), and
AmBisome (Gilead, Astellas Pharma US, Inc.) were obtained
from local pharmacies. The negatively charged N-carbamyl-poly
(ethylene glycol methyl ether)-1,2-distearoyl-sn-glycerol-3-
phospho-ethanolamine triethyl ammonium salt (PEG-DSPE),
having PEG moieties of 350 Da, 2 kDa, and 12 kDa (0.35K-
PEG-DSPE; 2K-PEG-DSPE; 12K-PEG-DSPE, respectively),
and the uncharged 3-methoxy polyethylene glycol-oxycarbonyl
3-amino-1,2-propandiol distearoyl ester having a PEG moiety of
2 kDa (2K-PEG-DS), were from Alza Corp. (Mountain View,
California).18 The uncharged 3-methoxy-polyethelene glycol
1,2-distearoyl glycerol (2K-PEG-DSG) was from NOF Corp.
(Tokyo, Japan).
Human serum samples from healthy volunteer donors,
obtained through an institutionally approved phlebotomy
protocol, were stored at -70°C until use.
Preparation and characterization of liposomes and micelles
The freeze-dried lipid components (originally dissolved in
tertiary butanol) were hydrated in 10 mL sterile pyrogen-free
normal saline (NS) by vortexing for 2-3 minutes at 70°C to form
multilamellar vesicles (MLVs). The MLVs were downsized
through 0.4- and 0.1-μm polycarbonate filters in two steps, 10
times through each, using a 10-mL extruder barrel from Northern
Lipids (Vancouver, British Collumbia, Canada) at 62°C.
Liposomes were suspended in 0.5 M NaCl/5 mM histidine
buffer (pH 6.5). Micelles were prepared by extensive vortex
mixing of 2K-PEG-DS-PE or 2K-PEG-DS in saline at 2 mg/mL,
followed by filtration through 0.22-μm filters. The phospholipid
concentration of preparations was determined using a modifica-
tion of Bartlett's procedure.19 Particle size distribution was
determined by dynamic light scattering (DLS), using an ALV-
NIBS/HPPS High Performance Particle Sizer with ALV-5000/
EPP multiply digital correlator (ALV-Laser Vertriebsge-
sellschaft GmbH, Langen, Germany). Liposome surface poten-
tial was determined by measuring 4-heptadecyl-7-
hydroxycoumarin ionization over a broad range of pH values
as described earlier.20 Table 2 shows the essential characteristics
of all preparations used.
Determination of bacterial endotoxin (LPS) in
liposome dispersions
The LPS content of liposomes prepared for this study was
determined by a Limulus amebocyte lysate assay (PYROGENT
Plus, Cat. No. N284-06, Cambrex Bio Science Walkersville,
Inc., Walkersville, Maryland), after dissolving (96% ethanol)
and separating (ultrafiltration using 20 kDa cutoff membrane)
the lipids from LPS.21 Acceptance criterion as pyrogen-free was
≤ 0.5 endotoxin units (EU)/mL (0.01-0.25 ng LPS/mL).
Measurement of complement activation in vitro
Liposomes were incubated with undiluted normal human
serum (NHS) in a shaking water bath, and C activation was
estimated by measuring the formation of S protein-bound C-
terminal complex (SC5b-9) with an enzyme-linked immuno-
sorbent assay (ELISA; Quidel Co., San Diego, California), as
described earlier.22,23 In a typical experiment we mixed 10 μL
liposomes with 40 μL serum in Eppendorf tubes, which were
Table 1
Vesicle structural factors analyzed for complement reactogenicity
Variables Character or range
Surface
PEG
Density 0.3-5.0%
Chain size 0.35, 2, and 12 kDa or none
Lipid anchor
charge
Phosphatidylethanolamine
vs. distearoyl or
distearoylglycerol oxycarbonyl
3-amino-1,2-propandiol; (intravenous)
Vesicle
features
Type of
phospholipid assembly
Micelle,
bilayer vesicle
Payload Doxorubicin, cisplatin,
amphotericin B, none (PBS)
Phospholipid
composition
HSPC, HSPG, EPC, DSPE
Surface charge Zeta potential
(from -60 to +1 mV)
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then incubated for 30 minutes at 37°C in a shaking water bath
(shaking rate of 80 rpm). The reaction was stopped by adding
20 volumes of 10 mM EDTA, 25 mg/mL bovine serum
albumin, 0.05% Tween 20, and 0.01% thimerosal (pH 7.4)
(i.e., the “sample diluent” of the SC5b-9 ELISA kit,
supplemented with EDTA).
Morphological analysis of liposomes by differential interference
contrast (DIC) and cryotransmission electron microscopy
(cryo-TEM)
A light microscope with DIC (Nomarski) optics was used to
examine the presence of aggregates in various liposome
preparations. A small drop of the liposome stock solutions was
placed in a concave well of a glass slide and covered with a
coverglass. The cryo-TEM analysis of liposomes was performed
by methods described earlier.24,25
Animal studies
Experiments using pigs were performed at the Uniformed
Services University of the Health Sciences (USUHS) and at
Semmelweis Medical University in Hungary. They were
approved by the local Animal Subject Review Committees and
followed their guidelines, treating the animals humanely. Swine
(25-40 kg) of both sexes were purchased from local vendors.
They were sedated with intramuscular ketamine (500 mg) and
anesthetized with 2% isoflurane, using an anesthesia machine, or
with intravenous nembutal (30 mg/kg). A pulmonary artery
catheter was advanced via the right internal jugular vein through
the right atrium into the pulmonary artery to measure pulmonary
artery pressure (PAP). Systemic arterial pressure (SAP) was
measured in the femoral artery. Other details of surgery,
instrumentation, and hemodynamic analysis were described
previously.13,15,23
Drug treatments
The indicated amounts of liposomes and other test materials
were diluted in phosphate buffered saline (PBS) and injected into
the pulmonary artery as a bolus, via the pulmonary arterial
catheter. Liposomes were flushed into the circulation with 5-10
mL PBS.
Quantifying of physiological changes during liposome reactions
Liposome reactions were quantified with the cardiac
abnormality score (CAS), a semiquantitative measure of the
severity of cardiac electric, circulatory (systemic and pulmo-
nary), and skin changes during CARPA.26 Scores of 0 to 5 imply
no response (CAS: 0), minimal (CAS: 1), mild (CAS: 2),
moderate (CAS: 3), severe (CAS: 4), and lethal (CAS: 5)
reactions.26 The symptoms specifying different CAS values are
specified in the legend to Table 3.
Statistical analysis
Data from the in vitro C assays are expressed as mean of
triplicate determinations ± SD. Multiple group comparisons were
done by analysis of variance followed by the Student-Neuman-
Keuls post-hoc test. Differences between groups were consid-
ered significant at P b 0.05.
Results
Interindividual and interbatch variation of complement activa-
tion by Doxil and AmBisome in vitro
In previous studies we demonstrated substantial individual
variation of Doxil-induced C activation in NHS.14 Also, in
preliminary studies we found that different Doxil or Calyx
batches display different capabilities to activate C in NHS. Thus,
for the present dissection of liposomal structural factors
Table 2
Composition and physicochemical characteristics of liposomes
Name Composition Lipid mole
ratio
Mean size∗
(nm)
Surface potential
(mV)
Zeta potential
(mV)
Doxil HSPC-Chol-2K-PEG-DSPE + doxorubicin 57 : 38 : 5 108 ND -13.3
Placebo Doxil HSPC-Chol/2K-PEG-DSPE 124 -52 -10.1
SPI-77 HSPC/Chol/2K-PEG-DSPE + cisplatin 116 ND -9.8
Placebo Doxil with small (0.35K) PEG HSPC-Chol-0.35K-PEG-DSPE 127 ND ND
Placebo Doxil with large (12K) PEG HSPC-Chol-12K-PEG-DSPE 128 ND ND
Neutral placebo Doxil HSPC-Chol-2K-PEG-DS 111 -12.3 -0.79
Placebo Doxil with low PEG density HSPC-Chol-2K-PEG-DSPE 55 : 44 : 0.6 121 ND -10.3
Cholesterol-free Doxil HSPC-2K-PEG-DSPE+ doxorubicin 95 : 5 84 ND -10.1
Cholesterol-free placebo Doxil HSPC-2K-PEG-DSPE 80 -52 -10.1
Highly negative LUV HSPC-Chol-HSPG 38 : 28 : 34 135 -81.3 -52.5
AmBisome HSPC-Chol-DSPG-Vit E + amphotericin B 49 : 23 : 18 :
0.3 : 9
141 ND -4,3
Neutral LUV HSPC-Chol 57 : 43 135 0 -4.6
Neutral placebo Doxil with EPC EPC-2K-PEG-DSG (EPC-PEG-DSG) 92.5 : 7.5 70 -17.5 0.7
PEG-PE micelles 2K-PEG-DSPE 100% 25 –141 -9.0
PEG-DS micelles 2K-PEG-DS 100% 25 -19 -1.3
MLV DMPC-Chol-DMPG 45 : 50 : 5 N1000 ND -58.5
∗ Mean size was determined by DLS in 5% (w/v) dextrose, triplicate measurements with SD b10%. ND, not done.
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contributing to C activation, we used a preselected highly
reactive Doxil batch as the source of liposomal doxorubicin (i.e.,
Doxil) and a highly reactive NHS as serum source. Doxil in this
serum caused significantly greater C activation than the equivalent
empty liposomes (placebo Doxil) as well as all other tested
doxorubicin-free liposomes differing in surface charge (Figure 1,
A) or PEG parameters (Figure 1, B). These observations suggest
that the presence of doxorubicin in liposomes was a major
contributor to C activation. However, compared to baseline, empty
liposomes were also triggers of C activation, and we observed
small but significant differences among their activities. In
particular, the presence of 5% PEG-PE on the surface, regardless
of PEG chain length (350, 2000, or 12,000 Da, Figure 1, B),
slightly accelerated C activation compared to neutral DS-PE-
containing vesicles as well as PEG-free HSPC-Chol vesicles, or
reduced (1%) 2K-PEG-PE-containing liposomes, which were
nonactivators. Figure 1, B also raises the possibility that the highly
extended and possiblymultiply coiled 12K-PEG onDSPE (inset in
Figure 1) might provide some protection against C activation by
phosphate diester PEG-DSPE. Consistent with the causal role of
surface charge in reactivity, the strongly negative HSPC-Chol-
HSPG caused much stronger activation than the comparable, less
negative vesicles (Figure 1, B).
As for the possible contribution of free doxorubicin to C
activation by Doxil, Figure 1, C shows that incubation of 50 μg/
mL free doxorubicin with serum led to no, or minimal C
activation. Taken together with the fact that free doxorubicin in
Doxil is b5-10% of total doxorubicin10 (i.e., b2.5-5 μg/mL in
serum upon incubation), it is unlikely that free doxorubicin at a
dose 10 to 20-fold (at 5–10%) lower than the above minimally
activating dose would be a major contributor to C activation.
Figure 2, A and B show further in vitro C tests in NHS
wherein AmBisome, a highly negatively charged (16% DSPG-
containing) antifungal (amphotericin B-containing) liposome
formulation (Figure 2, A) and three more Doxil look-alikes
(Figure 2, B) were assessed for SC5b-9 production in multiple
NHS, using zymosan as positive control. AmBisome turned out
to be a very strong C activator in each of 20 tested NHS samples,
whereas SPI-77, a liposomal formulation having identical lipid
composition to Doxil, but passively loaded with cisplatin (also
referred to as “Stealth cisplatin”),27 caused no significant C
Table 3
Cardiopulmonary responses of pigs to different liposomes
Liposome or micelle Bolus dose
(nmol phospholipid/kg)
Reaction
5-30 30-150 150-1000 1000-104 CAS∗ n/all
Doxil 6 1 5 0 1/19
1 2-3 1/19
3 4 8/19
3 5 9/19
Placebo Doxil 1 1 0 2/6
1 2 1/6
3 3 3/6
SPI-77 2 0 2/2
Placebo Doxil with
small (0.35K) PEG
2 0 2/3
1 2-3 1/3
Placebo Doxil with
large (12K) PEG
1 3 1/3
2 4 2/3
Neutral placebo Doxil 3 1 0 1/4
1 3/4
Placebo Doxil with
low PEG density
1 0 1
Cholesterol-free
Doxil
2 3 2/2
Cholesterol-free
placebo Doxil
2 1 2 1/2
1 1/2
Highly negative
LUV
3 2 2-3 3/5
5 2/5
AmBisome 5 4 4/5
5 1/5
Negative EPC LUV 2 4 2/4
2 5 2/4
Neutral LUV 1 4 1 0 6/6
Neutral placebo
Doxil with EPC
1 5 1/1
PEG-PE micelles 2 0 2/2
PEG-DS micelles 2 0 2/2
MLV 40 4 35/40
5 8/40
Zymosan N/A N/A N/A N/A 4-5 100/100
∗ The symptoms specifying different CAS values were as follows: CAS-1,
small but significant changes in PAP or SAP with minimal or no changes in
EKG and/or cardiac output (CO) and/or partial pressure of CO2 (PCO2);
CAS-2, noticeable rises of PAP with mild arrhythmia (tachycardia and/or
bradycardia, initial rise followed by small declines in SAP, CO, and PCO2);
CAS-3, more expressed changes in these parameters, but not reaching
physiological limits (e.g., 80 mmHg PAP, 40 mmHg SAP); CAS-4, massive,
but still reversible changes in all variables; CAS-5, cardiac arrest with or
without ventricular fibrillation, fatal unless the animal is salvaged with
epinephrine, cardiac massage, or both.
Figure 1. Complement activation by liposomes in a Doxil-sensitive normal
human serum. The bars represent percentage increase of SC5b-9 over
baseline after 40 minutes' incubation at 37°C. Error bars are standard
deviation (SD) for duplicate or triplicate wells. Black and gray shadings
represent negative and neutral surface charges, respectively. (A) Roles of
doxorubicin and surface charge. (B) Comparison of placebo Doxil with
different PEG size and density. (C) An independent experiment in which 50
μg/mL free doxorubicin was incubated with 20 samples of undiluted NHS as
described for liposomes. The insert illustrates the size difference among the
PEG-PEs used.
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activation. Nor did EPC containing 5 mol% 2K-PEG-DSPE
and EPC containing 5 mol% uncharged 2K-PEG-DSG. These
observations provide further examples for the strong reacto-
genicity of PG when applied in relatively high amounts. Of
note, the effect of free amphotericin B could not be tested due
to its low water solubility.
In a further experiment we looked at the C-activating effects
of 2K-PEG-PE micelles in two Doxil-reactive sera and found no
apparent rise of SC5b-9 (data not shown), at least at
concentrations corresponding to the amount of PEG-PE in
Doxil (3.2 mg/mL).
In vivo reactogenicity of different liposomes in pigs
Depending on type, dose, and administration schedule,
liposomes can trigger massive hemodynamic and cardiopulmo-
nary changes in pigs. The reaction is illustrated for AmBisome in
Figure 3, whose bolus injection at 0.01 mg/kg caused greater
Figure 2. In vitro studies similar to those in Figure 1, showing individual data points (mean of duplicate determinations). In (B), identical symbols represent
identical serum donors. (A) and (B) show different experimental series.
Figure 3. Cardiopulmonary changes following bolus administration of AmBisome (0.01 mg/kg, 80 nmol phospholipid/kg) in a pig (typical out of five). Upper
panels are real-time recordings showing the pulse amplitude; lower panels show averaged blood pressure values. The arrow shows the moment of liposome
administration.
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than threefold (or N300%) rise of PAP and some 60% decline of
SAP within 1 minute. Steady state resumed within 3 minutes, at
supranormal for PAP and physiological pressure for SAP. Such
moderate to severe reactions occurred in all of five AmBisome-
injected pigs (Table 3) and all other pigs where, in Table 3,
“cardiopulmonary abnormality scores” (CAS) N3 are shown. As
detailed in the Methods and Table 3, CAS is a composite
measure of CARPA, derived from grouping the symptoms of
mild, moderate, severe, and lethal reactions.26
Table 3 presents the dose dependence, frequency, and grade
of cardiopulmonary response of pigs to different liposomes,
using CAS as end point. Consistent with the in vitro SC5b-9
measurements, AmBisome, Doxil, and zymosan caused the
strongest, mostly severe or lethal (CAS 4-5) reactions, whereas
SPI-77, despite its identical size distribution and lipid
composition to Doxil,27 caused neither C activation in serum
nor reaction in pigs. Although minimal to mild reactions did
occur with liposomes that caused no apparent rise of SC5b-9
in NHS (e.g., EPC-Chol having 5 mol% 2K-PEG-DSG and
HSPC having 5 mol% 2K-PEG-DS) (Figure 4), considering
the mentioned individual variation of in vitro C response to
liposomes, it cannot be excluded that a larger number of serum
tests would have revealed the C-activating capability of those
liposomes as well. This implies that the pig model is more
sensitive than the in vitro assay in revealing acute immune
reactivity.
The shape of liposomes is modified by doxorubucin
remote loading
Figure 5, A shows that those liposomes in Doxil wherein
the doxorubicin sulfate crystal “disks” are relatively “thick”
are also elongated. These liposomes have oval, coffee bean-
like shape in contrast to the spherical shape of vesicles with
no or “thin” disks. This suggests that the disks, if their
physical measures exceed the space available within the
aqueous phase of liposomes, elongate the vesicles in one
direction. In support of this concept, the shapes of SPI-77
(Figure 5, B) and placebo Doxil (Figure 5, C) liposomes
were highly symmetrical and spherical. Considering that the
equatorial belt of oval particles have, along their longer axis,
lower curvature than that of corresponding spheres, the
ovaliform transition of Doxil liposomes implies an increase
of flat surface area, at least in one dimension. In addition to
the above shape change of individual liposomes, DIC
microscopy in a C-reactive commercial Doxil vial revealed
the presence of multimicron aggregates, with intercalated red
material that corresponds to extravesicular doxorubicin (Figure
5, D-F). These aggregates have in all dimensions large,
nonsmooth surfaces that are partially covered by extravesi-
cular doxorubicin, another major increase of blood-exposed
flat liposome surface. Although at this stage we do not have
quantitative assessment of doxorubicin-induced shape changes
and related surface expansion in Doxil, these morphological
observations highlight at least two possibilities for membrane
structural changes caused by doxorubicin that may account
for increased C activation.
Discussion
The main goal of this study was to explore yet unknown
structural factors in liposomes that might influence their C-
activating and anaphylactogenic potentials. The clinical rele-
vance of the subject lies in the increased risk for non-IgE-
mediated infusion reactions in patients treated for the first time
with many liposomal drugs, including Doxil, AmBisome,
Abelcet, Amphocyl, and Daunoxome.10-12,14,16,28-36 Although
slow initial infusion and premedication with corticosteroids and
antihistamines are effective in reducing the frequency of
CARPA,37 reactions still occur in up to 10% of patients treated
with Doxil despite slow infusion and/or premedication.10
The present study focused primarily on C activation and in
vivo reactogenicity of Doxil, the first liposomal nanomedicine,
which has been for many years successfully used in cancer
chemotherapy.6,7,28-33,38 Initially it was thought that steric
stabilization with PEG should protect against C binding to
liposomes39; however, more recent studies proved that Doxil is a
strong C activator,14,37 partly as a consequence of the net anionic
charge of the phosphate moiety on 2K-PEG-PE.17
To explore further structural features of Doxil that might
contribute to C activation, here we performed head-to-head
comparison of C activation and in vivo reactogenicity of
commercial Doxil and equivalent drug-free vesicles, differing
from Doxil and from each other in one feature at a time. These
features were surface charge, PEG phospholipid anchor charge,
PEG size and density, and particle lipid composition and
structure. We also studied the role of liposomal payload by
comparing Doxil with placebo Doxil and Stealth cisplatin, which
are identical to Doxil in lipid composition and size but differ in
their payload. The role of net surface charge was assessed by
testing HSPG-containing (strongly negative) liposomes and
AmBisome, whereas the influence of PEG phospholipid anchor
charge was tested using uncharged PEG-DS and PEG-DSG. The
surface density of PEG was assessed by comparing the effects of
0.6% (when the PEG is in the mushroom conformation)40 with
Figure 4. Continuous records of systemic arterial pressure (SAP) changes
caused by bolus injection of Doxil and two of its doxorubicin-free neutral
derivatives. Illustration of the minimal reactogenicity of PEGylated neutral
LUVs. These test agents were administered to different pigs as first bolus.
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5% 2K-PEG-PE (when the PEG is in a transition between the
mushroom and brush conformations).40 The role of PEG chain
length was established by comparing Doxil-like large unilamel-
lar vesicles (LUVs) prepared with 2 K-, 0.35 K-, and 12 K-PEG-
PE. Finally, to explore the impact of particle structure,
lipopolymer micelles with different head group (2K-PEG-
DSPE, 2K-PEG-DS, 2K-PEG-DSPG, 2K-PEG-EPG) were
tested. As positive controls for liposome-induced C activation
and cardiopulmonary reactions we used multilamellar DMPC-
Chol-DMPG liposomes (MLVs) and zymosan, which were
shown earlier to be potent C activators and CARPA inducers in
pigs.13-16
Analysis of the effects of the above vesicle parameters in a
Doxil-sensitive NHS showed major and minor impacts. The
two liposome variables that led to major increases in C
activation were the presence of doxorubicin and expressed net
negative surface charge on vesicles, whereas all other listed
permutations of surface properties caused minor impact on
SC5b-9 formation. The massive C-activating effect of Doxil,
just like that of AmBisome, could not be explained by LPS
contamination, as these commercial formulations are consid-
ered pyrogen-free. Likewise, the strong C-activating effect of
(negatively charged) drug-free liposomes is hardly explainable
by endotoxin contamination because, upon their preparation,
they had ≤0.5 EU/mL LPS (≤0.01-0.25 ng LPS/mL), which is
six to eight orders of magnitude lower than the reported
minimum concentration of LPS (200-500 μg/mL),41,42 causing
short-term (within 1 hour) C activation in human plasma or
serum. Nevertheless, in light of the fact that our assays were
not run aseptically, and that nanoparticles can enhance the
immunostimulatory properties of endotoxin,43,44 some minor
influence of LPS on the changes we observed cannot a priori
be ruled out.
The finding that doxorubicin-containing liposomes led to
significant increase of SC5b-9 formation, whereas free
doxorubicin was probably not a contributor to this effect,
suggests that doxorubicin's action might be indirect, via
modifying the surface of liposomes. According to our electron
microscopic analysis, one potential Doxil-specific surface
alteration might arise from the presence of elongated
doxorubicin crystals in the aqueous space of Doxil, forcing
an ovaliform transition of spherical vesicles with an increase in
the ratio of flat vs. highly curved areas on the bilayer surface.
The other Doxil-specific surface effect was the formation of
multimicron aggregates that yield large, flat, incongruent
surfaces. The coffee-bean, or American football-like oval
appearance of Doxil is widely documented in the literature;
what our presented cryo-TEM images highlight for the first
Figure 5. Cryo-TEM images of (A) Doxil; (B) SPI-77 (equivalent liposomes with cisplatin payload), and (C) placebo Doxil (i.e., Doxil without doxorubicin).
(D–F) DIC microscopy of Doxil aggregates with doxorubicin seen as red gluelike material intercalated among the vesicles. Bars are 100 nm.
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time to our knowledge is that this shape change may be related
to the length and bulkiness of doxorubicin crystals within
liposomes. Considering that C activation proceeds on mem-
brane surfaces whose curvature is an important factor45 in
determining the buildup of multimolecular complexes, such as
the C3 convertases (C4b2b or C3bBb) and C5 convertases
(C4b2b3b or C3bBb3b), the low-curvature parts in the case of
oval Doxil vesicles, together with the visibly large, incongru-
ent surfaces on aggregates, may explain, at least in part, the
increased reactogenicity of Doxil.
The C activation-promoting activity of negative surface
charges on liposomes is a well-established phenomenon.12,22
What is new information in the present study is that AmBisome
causes massive C activation in NHS essentially without
individual variation (strong activation was present in all of 20
tested NHS samples). In this aspect, AmBisome significantly
differs from Doxil, in that the latter causes strong C activation
only in certain sensitive sera, which phenomenon also shows
some interbatch variation most likely as a consequence of
variable storage time (data not shown).
As for the impact of particle type, our limited analysis in the
present study showed neither C activation, nor reactivity in pigs
of anionic micelles formed from PEG-DSPE and its noncharged
modifications. However, it is not clear if this is due to the small
size of the micelles or the fact that their PEG chains are densely
packed in a brush conformation that is highly extended and
prevents interaction with proteins at the micellar lipid/water
interface. Thus, unlike mixed-lipid micelles of Cremophor EL,
which are strong C activators,22,46 the better defined PEG-DSPE
micelles may be free from such side effects. One possible
explanation is a lack of ready fusion with lipoproteins to form
large particles, as the surface of 10 to 20 nm individual micelles is
too small to accommodate direct deposition of C convertases.46
In conclusion, this study showed that for nanoliposomes the
choice of PC, the carbon chain length, and surface density of
PEG-PE have minor or no effect, whereas liposomal surface
charge and the presence of a shape-modifying drug, such as
doxorubicin, are major contributors to liposome-induced C
activation and related HSRs. Attention to these correlations
and appropriate optimization of vesicle parameters might help
in reducing the risk of infusion reactions to liposomal drugs.
References
1. Goyal P, Goyal K, Gurusamy S, Kumar V, Singh A, Katare Opnath
Mishra DN. Liposomal drug delivery systems–clinical applications.
Acta Pharm 2005;55:1-25.
2. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic
science, rationale, and clinical applications, existing and potential. Int J
Nanomedicine 2006;1:297-315.
3. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications
and hazards. Int J Nanomedicine 2008;3:133-49.
4. Torchilin V. Antibody-modified liposomes for cancer chemotherapy.
Expert Opin Drug Deliv 2008;5:1003-25.
5. Marcato PD, Durán N. New aspects of nanopharmaceutical delivery
systems. J Nanosci Nanotechnol 2008;8:2216-29.
6. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal
anthracyclines: from basics to clinical applications. J Control Release
1998;53:275-9.
7. Amselem S, Gabizon A, Barenholz Y. Optimization and upscaling of
doxorubicin-containing liposomes for clinical use. J Pharm Sci
2006;79:1045-52.
8. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner
D, et al. Liposomal amphotericin B for empirical therapy in patients with
persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
9. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arietta A, et
al. A randomized, double-blind comparative trial evaluating the safety of
liposomal amphotericin B versus amphotericin B lipid complex in the
empirical treatment of febrile neutropenia. Clin Infect Dis
2000;31:1155-63.
10. Doxil. Package label. Available from: http://www.Doxil.com.
11. Ambisome. Package label. Available from: http://www.ambisome.com.
12. Szebeni J. The interaction of liposomes with the complement system.
Crit Rev Ther Drug Carrier Syst 1998;15:57-88.
13. Szebeni J, Baranyi B, Savay S, Bodo M, Morse DS, Basta M, et al.
Liposome-induced pulmonary hypertension: properties and mechanism
of a complement-mediated pseudoallergic reaction. Am J Physiol
2000;279:H1319-28.
14. Szebeni J, Baranyi B, Savay S, Lutz LU, Jelezarova E, Bunger R. The
role of complement activation in hypersensitivity to pegylated liposomal
doxorubicin (Doxil). J Liposome Res 2000;10:347-61.
15. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins
DE, et al. Hemodynamic changes induced by liposomes and liposome-
encapsulated hemoglobin in pigs: a model for pseudo-allergic
cardiopulmonary reactions to liposomes. Role of complement and
inhibition by soluble CR1 and anti-C5a antibody. Circulation
1999;99:2302-9.
16. Szebeni J. Complement activation-related pseudoallergy: a new class of
drug-induced immune toxicity. Toxicology 2005;216:106-21.
17. Moghimi SM, Hamad I, Andresen TL, Jörgensen K, Szebeni J.
Methylation of the phosphate oxygen moiety of phospholipid-methoxy
(polyethylene glycol) conjugate prevents PEGylated liposome-mediated
complement activation and anaphylatoxin production. FASEB J
2006;20:2591-3.
18. Priev A, Zalipsky S, Cohen R, Barenholz Y. Determination of critical
micelle concentration of lipopolymers and other amphiphiles: compar-
ison of sound velocity and fluorescent measurements. Langmuir
2002;18:612-7.
19. Shmeeda H, Even Chen S, Honen R, Cohen R, Weintraub C, Barenholz
Y. Enzymatic assays for quality control and pharmacokinetics of
liposome formulations: comparison with nonenzymatic conventional
methodologies. Methods Enzymol 2003;367:272-92.
20. Zuidam NJ, Barenholz Y. Electrostatic parameters of cationic liposomes
commonly used for gene delivery as determined by 7-heptadecyl-4-
hydroxycoumarin. Biochim Biophys Acta 1997;1329:211-22.
21. Schmidtgen M, Brandl M. Detection of lipopolysaccharides in
phospholipids and liposomes using the limulus test. J Liposome Res
1995;5:109-16.
22. Szebeni J, Muggia FM, Alving CR. Complement activation by
Cremophor EL as a possible contributor to hypersensitivity to paclitaxel:
an in vitro study. J Natl Cancer Inst 1998;90:300-6.
23. Szebeni J, Baranyi L, Savay S, Milosevits J, Bodo M, Bunger R, et al.
The interaction of liposomes with the complement system: in vitro and in
vivo assays. Methods Enzymol 2003;373:136-54.
24. Bellare JR, Davis HT, Scriven LE, Talmon Y. Controlled environment
vitrification system: an improved sample preparation technique. J
Electron Microsc Tech 1988;10:87-111.
25. Talmon Y. Cryogenic temperature transmission electron microscopy in
the study of surfactant systems. In: Binks BP, editor. Modern
characterization methods of surfactant systems. New York: Marcel
Dekker; 1999. p. 147-78.
26. Szebeni J, Baranyi L, Sávay S, Bodó M, Milosevits J, Alving CR, et al.
Complement activation-related cardiac anaphylaxis in pigs: role of C5a
anaphylatoxin and adenosine in liposome-induced abnormalities in ECG
and heart function. Am J Physiol 2006;290:H1050-8.
8 J. Szebeni et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2011) xxx–xxx
27. Peleg-Shulman T, Gibson D, Cohen R, Abra R, Barenholz Y.
Characterization of sterically stabilized cisplatin liposomes by nuclear
magnetic resonance. Biochim Biophys Acta 2001;1510:278-91.
28. Dezube BJ. Safety assessment: DoxilR (doxorubicin HCl liposome injection)
in refractory AIDS-related Kaposi's sarcoma. In: Alberts DS, Garcia DJ,
editors. Doxil clinical series, Vol. 1. Califon, New Jersey: Gardiner-Caldwell
SynerMed; 1996. p. 1-8.
29. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, et al.
Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol
1994;33:779-86.
30. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory
study with pharmacokinetics in patients with hormone-refractory
prostate cancer. Anticancer Drugs 2000;11:123-7.
31. Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by
pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998;9:45-50.
32. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al.
Prolonged circulation time and enhanced accumulation in malignant
exudates of doxorubicin encapsulated in polyethylene-glycol coated
liposomes. Cancer Res 1994;54:987-92.
33. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal
doxorubicin in patients with cancer. Drugs 1997;54(Suppl 4):30-45.
34. Lyass O, Hubert A, Gabizon AA, Phase I. study of Doxil-cisplatin
combination chemotherapy in patients with advanced malignancies. Clin
Cancer Res 2001;7:3040-6.
35. Lenz HJ. Management and preparedness for infusion and hypersensi-
tivity reactions. Oncologist 2007;12:601-9.
36. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an
old drug into a new form of chemotherapy. Cancer Invest 2001;19:
424-36.
37. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR,
et al. Complement activation following first exposure to pegylated
liposomal doxorubicin (Doxil): possible role in hypersensitivity re-
actions. Ann Oncol 2003;14:1430-7.
38. Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P,
et al. Role of complement activation in hypersensitivity reactions to
Doxil and HYNIC-PEG liposomes: experimental and clinical studies.
J Liposome Res 2002;12:165-72.
39. Utkhede DR, Tilcock CP. Studies upon the toxicity of polyethylene
glycol coated lipid vesicles: acute hemodynamic effects, pyrogenicity
and complement activation. J Liposome Res 1998;8:537-50.
40. Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome
size and on compressibility and packing of lipid bilayer. Chem Phys
Lipids 2005;135:117-29.
41. Roeise O, Garred P, Mollnes TE, Aasen AO. Studies on the dose
dependence of endotoxin-induced in vitro activation of the complement
system. Eur Surg Res 1989;21:34-42.
42. Szebeni J, Wassef N, Spielberg H, Rudolph AS, Alving CR.
Complement activation by liposome-encapsulated hemoglobin in vitro.
The role of endotoxin contamination. Artif Cells Blood Substit Immobil
Biotechnol 1995;23:355-63.
43. Inoue K, Takano H. Aggravating impact of nanoparticles on immune-
mediated pulmonary inflammation. Sci World J 2011;11:382-90.
44. Shin JA, Lee EJ, Seo SM, Kim HS, Kang JL, Park EM. Nanosized
titanium dioxide enhanced inflammatory responses in the septic brain of
mouse. Neuroscience 2010;165:445-54.
45. PedersenMB,ZhouX,LarsenEK, SørensenUS,Kjems J,Nygaard JV, et al.
Curvature of synthetic and natural surfaces is an important target feature in
classical pathway complement activation. J Immunol 2010;184:1931-45.
46. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, et al.
Formation of complement-activating particles in aqueous solutions of
Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol
2001;1:721-35.
9J. Szebeni et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2011) xxx–xxx
Graphical Abstract
Nanomedicine: Nanotechnology, Biology, and Medicine xx (2011) xxx–xxx–
Liposome-induced complement activation and related cardiopulmonary distress
in pigs: factors promoting reactogenicity of Doxil and AmBisome
János Szebeni, MD, PhD, DSc a,⁎,1, Péter Bedőcs, MD b,1, Zoltán Rozsnyay, MSc, PhD c,
Zsóka Weiszhár, MSc c, Rudolf Urbanics, MD, PhD c, László Rosivall, MD, PhD, DSc d,
Rivka Cohen, PhD e, Olga Garbuzenko, PhD e, György Báthori, MD, PhD f,
Miklós Tóth, MD, PhD, DSc g, Rolf Bünger, MD, PhD h, Yechezkel Barenholz, PhD e
aNanomedicine Research and Education Center, Bay Zoltan Foundation for Applied Research, Semmelweis University,
and Department of Pathophysiology, Miskolc University, Faculty of Health, and Seroscience Ltd., Budapest, Hungary
bSemmelweis University, Budapest, Hungary, and Department of Anatomy, Physiology and Cell Biology,
Uniformed Services University of Health Sciences, Bethesda, Maryland, USA
cSeroscience Ltd., Budapest, Hungary
dDepartment of Pathophysiology, Faculty of Medicine, Semmelweis University, Hungarian Academy of
Sciences-Semmelweis University, Nephrology Research Group, Budapest, Hungary
eLaboratory of Membrane and Liposome Research, Hebrew University-Hadassah Medical School, Jerusalem, Israel
fNanomedicine Research and Education Center, Bay Zoltan Foundation for Applied Research,
and Semmelweis University, Budapest, Hungary
gDepartment of Health Science and Sport Medicine, Faculty of Physical Education and Sport Science, Semmelweis Medical
University, Budapest, Hungary
hDepartment of Anatomy, Physiology and Cell Biology, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA
Blood pressure changes in pigs following bolus administration of AmBisome.
Nanomedicine: Nanotechnology, Biology, and Medicine
xx (2011) xxx
nanomedjournal.com
